Posts tagged as:

dopamine agonist

Neupro Patch for Parkinson’s Disease Recalled by FDA

May 13, 2008

Neupro patches were approved by the FDA for Parkinson’s disease treatment in September 2007. They proved to be very effective in the control of Parkinson symptoms, as compared to the effects of other dopamine agonists including Mirapex and Requip. Unfortunately, in March, the FDA recalled Neupro due to problem with the patch delivery of the [...]

Read the full article →

New Findings in Restless Legs Syndrome

October 8, 2007

One of the most frustrating neurological conditions is restless legs syndrome (RLS.) It is characterized by an intense overwhelming need to move your legs at night or when sitting or resting. This can be so severe that affected individuals have difficulty sitting through a movie or driving in a car for any distance. Occasionally [...]

Read the full article →

FDA Approves New Alzheimer’s Medication Patch

September 24, 2007

The FDA has recently approved the dementia fighting drug Exelon in a patch form. The new formulation, Transdermal Exelon, offers patients a new and unique way to get medication which can help with improving cognitive function and slow down memory loss in patients suffering from Alzheimer’s disease. The new patch is also FDA approved for [...]

Read the full article →

New Treatment Options for Parkinson’s Disease

August 16, 2007

The FDA has approved a new medication therapy for the treatment of Parkinson’s disease. The new drug is rotigotine (Neupro), which is in the family of dopamine agonists. Dopamine agonists mimic the effects of levodopa (Sinemet) without having to go through chemical transformation. Other dopamine agonists include Mirapex and Requip. Neupro is different in that [...]

Read the full article →